Physician profile
Grady B Core
NPI 1710088117
$3,763.73
in general payments reported to CMS, 2019-2025
13 companies · $861 in 2025
The $861 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $112 · 2021: $542 · 2022: $750 · 2023: $382 · 2024: $831 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $876.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $1,002.58 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer, Mentor Siltex Round Spectrum, Artoura Breast Tissue Expander |
| Abbvie INC. | $968.85 | 2023-2025 | Botox |
| Allergan, INC. | $540.13 | 2019-2023 | |
| Sientra, INC. | $331.96 | 2019-2021 | |
| Surgical Innovation Associates, INC. | $320.17 | 2022 | |
| Tela Bio, INC. | $182.56 | 2024 | Ovitex 2s |
| Revance Therapeutics, INC. | $148.06 | 2024-2025 | Daxxify |
| Motiva USA, LLC | $92.34 | 2024-2025 | |
| Galderma Laboratories, L.P. | $55.83 | 2019-2024 | |
| Integra Lifesciences Corporation | $43.54 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Eagle Pharmaceuticals, INC. | $30.66 | 2023 | |
| Kerecis Limited | $25.68 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Merz North America, INC. | $21.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grady Core listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.